Article Data

  • Views 1475
  • Dowloads 217

Reviews

Open Access

It's not over till it's over: a narrative review of Long COVID

  • Joseph V. Pergolizzi1
  • Jo Ann LeQuang1
  • Peter Magnusson2,3
  • Dariusz Myrcik4,5
  • Giustino Varrassi5

1NEMA Research Group, Naples, FL 34108-1852, USA

2Centre for Research and Development, Uppsala University/Region Gävleborg, 80188 Gävle, Sweden

3Cardiology Research Unit, Department of Medicine, Solna, Karolinska Institutet, 17177 Stockholm, Sweden

4Department of Internal Medicine, University of Silesia, 41813 Katoviche, Poland

5Paolo Procacci Foundation, Via Tacito 7, 00193 Rome, Italy

DOI: 10.22514/sv.2021.067 Vol.17,Issue 3,May 2021 pp.21-30

Submitted: 19 March 2021 Accepted: 26 March 2021

Published: 08 May 2021

*Corresponding Author(s): Jo Ann LeQuang E-mail: joannlequang@gmail.com

Abstract

Viral persistence following acute COVID infection is increasingly being reported by patients and gradually being recognized as a medical syndrome. Like much about COVID, this so-called Long COVID is perplexing. It is associated with numerous symptoms, foremost among them profound fatigue, and often occurs in a relapsing/remitting pattern. There is one “living” guideline for managing Long COVID and even terminology and definitions of the syndrome are in flux. Long COVID occurs in patients who have recovered from the acute infection and this may be viral persistence, a form of autoimmunity, or the long-term results of organ damage sustained during the acute infection. Symptoms have been reported up to six months after acute infection with no clear association between the severity of the acute infection and the presence or absence of Long COVID. The symptoms of the acute illness do not necessarily align with the symptoms of Long COVID. Disruptions to the autonomic function in Long COVID are particularly puzzling, including orthostatic intolerance syndrome (which may not have occurred during the acute infection). Loss of the sense of smell and taste is one symptom that appears common in both acute and Long COVID; on the other hand, fever is more prevalent in acute than Long COVID. Research is urgently needed to better understand Long COVID, for example: what is the role of elevated biomarkers such as D-dimer and C-reactive protein in Long COVID? Is Long COVID one or more than one syndrome? How can patients with Long COVID be appropriately treated?


Keywords

COVID-19; COVID therapy; Fatigue; Immunobiography; Long COVID; Long-haul COVID; Oxidative stress; Therapy


Cite and Share

Joseph V. Pergolizzi,Jo Ann LeQuang,Peter Magnusson,Dariusz Myrcik,Giustino Varrassi. It's not over till it's over: a narrative review of Long COVID. Signa Vitae. 2021. 17(3);21-30.

References

[1] Guillot X, Ribera A, Gasque P. Chikungunya-induced arthritis in reunion island: a long-term observational follow-up study showing frequently persistent joint symptoms, some cases of persistent chikungunya immunoglobulin m positivity, and no anticyclic citrullinated peptide seroconversion after 13 years. The Journal of Infectious Diseases. 2020; 222: 1740–1744.

[2] Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. The Lancet Infectious Diseases. 2015; 15: 905–912.

[3] Gorna R, MacDermott N, Rayner C, O’Hara M, Evans S, Agyen L, et al. Long COVID guidelines need to reflect lived experience. The Lancet. 2020; 397: 455–457.

[4] Ashton J. Long COVID—what doesn’t kill you may not make you stronger. Journal of the Royal Society of Medicine. 2020; 113: 466–467.

[5] Mahase E. COVID-19: what do we know about “Long COVID”? British Medical Journal. 2020; 370: m2815.

[6] Callard F, Perego E. How and why patients made Long COVID. Social Science & Medicine. 2021; 268: 113426.

[7] Nath A. Long-haul COVID. Neurology. 2020; 95: 559–560.

[8] Body Politic. Body Politic COVID-19 Support Group Newsletter. 2021. Available at: https://www.wearebodypolitic.com/bodytype/ 2021/1/5/the-preprint-youve-been-waiting-for (Accessed: 08 February 2021).

[9] Pergolizzi JV, LeQuang JA, Taylor R, Wollmuth C, Nalamachue M, Varrassi G, et al. Four pandemics: lessons learned, lessons lost. Signa Vitae. 2021; 17: 1–5.

[10] Barber C. The problem of ‘Long Haul’ COVID. 2020. Avail-able at: https://www.scientificamerican.com/article/the-problem-of-long-haul-COVID/ (Accessed: 05 February 2021).

[11] Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, et al. Long-COVID: an evolving problem with an extensive impact. South African Medical Journal. 2020; 111: 10–12.

[12] Mahase E. Long COVID could be four different syndromes, review suggests. British Medical Journal. 2020; 371: m3981.

[13] Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers. Journal of Medical Virology. 2021; 93: 2555–2556.

[14] Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in ‘Long COVID’: rationale, physiology and management strategies. Clinical Medicine. 2020; 21: e63–e67.

[15] Sivan M, Taylor S. NICE guideline on Long COVID. British Medical Journal. 2020; 371: m4938.

[16] Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection. The Journal of the American Medical Association. 2020; 324: 2251–2252.

[17] Soriano V, Ganado-Pinilla P, Sánchez-Santos M, Barreiro P. Unveiling Long COVID-19 disease. AIDS Reviews. 2020; 22: 227–228.

[18] Erku DA, Belachew SA, Abrha S, Sinnollareddy M, Thomas J, Steadman KJ, et al. When fear and misinformation go viral: Pharmacists’ role in deterring medication misinformation during the ‘infodemic’ surrounding COVID-19. Research in Social and Administrative Pharmacy. 2021; 17: 1954–1963.

[19] Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. The Journal of the American Medical Association. 2020; 324: 603–605.

[20] Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. Morbidity and Mortality Weekly Report. 2020; 69: 993–998.

[21] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021; 397: 220–232.

[22] Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Á Steig B, Gaini S, et al. Long COVID in the Faroe Islands-a longitudinal study among non-hospitalized patients. Clinical Infectious Diseases. 2020: ciaa1792. (in press)

[23] Moreno-Pérez O, Merino E, Leon-Ramirez J, Andres M, Ramos JM, Arenas-Jiménez J, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. Journal of Infection. 2021; 82: 378–383.

[24] Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nature Medicine. 2021; 27: 28–33.

[25] Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19—it’s not over until? Clinical Microbiology and Infection. 2021; 27: 506-508. (in press)

[26] Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infectious Diseases. 2020; 7: ofaa509.

[27] Vaira LA, Salzano G, Fois AG, Piombino P, De Riu G. Potential pathogenesis of ageusia and anosmia in COVID‐19 patients. International Forum of Allergy & Rhinology. 2020; 10: 1103–1104.

[28] Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020; 76: 396–398.

[29] Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020; 130: 1787.

[30] Suzuki M, Saito K, Min W, Vladau C, Toida K, Itoh H, et al. Identification of viruses in patients with postviral olfactory dysfunction. The Laryngoscope. 2007; 117: 272–277.

[31] Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology. 2020; 277: 2251–2261.

[32] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. JAMA Neurology. 2020; 77: 683–690.

[33] Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Science Advances. 2020; 6: eabc5801.

[34] Papa A, Salzano AM, Di Dato MT, Varrassi G. Images in practice: painful cutaneous vasculitis in a SARS-CoV-2 IgG-positive child. Pain and Therapy. 2020; 9: 805–807.

[35] McMahon DE, Gallman AE, Hruza GJ, Rosenbach M, Lipoff JB, Desai SR, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. The Lancet Infectious Diseases. 2021; 21: 313–314.

[36] Kingstone T, Taylor AK, O’Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the ‘right’ GP: a qualitative study of the experiences of people with long-COVID. BJGP Open. 2020; 4: bjgpopen20X101143.

[37] Raudenská J, Steinerová V, Javůrková A, Urits I, Kaye AD, Viswanath O, et al. Occupational burnout syndrome and post-traumatic stress among healthcare professionals during the novel coronavirus disease 2019 (COVID-19) pandemic. Best Practice & Research Clinical Anaes-thesiology. 2020; 34: 553–560.

[38] Nabavi N. Long COVID: how to define it and how to manage it. British Medical Journal. 2020; 370: m3489.

[39] Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Critical Reviews in Clinical Laboratory Sciences. 2020: 1–23.

[40] Lee M, Kang J, Jeong YJ. Risk factors for post-intensive care syndrome: a systematic review and meta-analysis. Australian Critical Care. 2020; 33: 287–294.

[41] Bienvenu OJ, Friedman LA, Colantuoni E, Dinglas VD, Sepulveda KA, Mendez-Tellez P, et al. Psychiatric symptoms after acute respiratory distress syndrome: a 5-year longitudinal study. Intensive Care Medicine. 2018; 44: 38–47.

[42] Myers EA, Smith DA, Allen SR, Kaplan LJ. Post-ICU syndrome: rescuing the undiagnosed. Journal of the American Academy of Physician Assistants 2016; 29: 34–37.

[43] Meeting the challenge of Long COVID. Nature Medicine. 2020; 26: 1803.

[44] Pergolizzi J, Raffa R, Fleischer C, Taylor R, LeQuang J. Chikungunya: basics for clinicians and their patients. Journal of General and Family Medicine. 2017; 1: 1–12.

[45] Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurology. 2011; 11: 37.

[46] Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiology. 2020; 5: 1265–1273.

[47] Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020; 191: 145–147.

[48] Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020; 136: 1342–1346.

[49] Sharma R, Sardar S, Mohammad Arshad A, Ata F, Zara S, Munir W. A patient with asymptomatic SARS-CoV-2 infection who presented 86 days later with COVID-19 pneumonia possibly due to reinfection with SARS-CoV-2. American Journal of Case Reports. 2020; 21: e927154.

[50] Centers for Disease Control and Prevention. Duration of isolation and precautions for adults with COVID-19. 2020. Available at: https: //www.cdc.gov/coronavirus/2019-ncov/hcp/duration isolation.html (Accessed: 30 January 2021).

[51] Halpin S, O’Connor R, Sivan M. Long COVID and chronic COVID syndromes. Journal of Medical Virology. 2020; 93: 1242–1243.

[52] Lokugamage AU, Bowen MA, Blair J. Long COVID: doctors must assess and investigate patients properly. British Medical Journal. 2020; 371: m4583.

[53] Franceschi C, Salvioli S, Garagnani P, de Eguileor M, Monti D, Capri M. Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Frontiers in Immunology. 2017; 8: 982.

[54] Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammag-ing: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews. Endocrinology. 2018; 14: 576–590.

[55] Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: do hyperinflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immunity & Ageing. 2020; 17: 23.

[56] De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Letters. 2005; 579: 2035–2039.

[57] Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and ‘Garb-aging’ trends in endocrinology and metabolism: Transmission Electron Microscopy. 2017; 28: 199–212.

[58] Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 2019; 25: 1822–1832.

[59] Rekatsina M, Paladini A, Piroli A, Zis P, Pergolizzi JV, Varrassi G. Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: a narrative review. Advances in Therapy. 2020; 37: 113–139.

[60] Ludvigsson JF. Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19. Acta Paediatrica. 2020; 110: 914–921.

[61] Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after COVID-19: qualitative study of 114 “Long COVID” patients and draft quality principles for services. BMC Health Services Research. 2020; 20: 1144.

[62] Greenhalgh T, Knight M. Long COVID: a primer for family physicians. American Academy of Family Physicians. 2020; 102: 716–717.

[63] Pergolizzi JV Jr, Raffa RB, Varrassi G, Magnusson P, LeQuang JA, Paladini A, et al. Potential neurological manifestations of COVID-19: a narrative review. Postgraduate Medical Journal. 2021; 1–11.

[64] Atherton H, Briggs T, Chew-Graham C. Long COVID and the importance of the doctor-patient relationship. British Journal of General Practice. 2021; 71: 54–55.

[65] The Lancet. Facing up to Long COVID. The Lancet. 2020; 396: 1861.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top